A Mathematical Model for Minimizing Add-On Operational Cost in Electrical Power Systems Using Design of Experiments Approach

One of the key functions of the Distribution System Operators (DSOs) ofelectrical power systems (EPS) is to minimize the transmission anddistribution power losses and consequently the operational cost. Thisobjective can be reached by operating the system in an optimal mode which is performed by adjusting control parameters such as on-load tap changer (OLTC) settings of transformers, generator excitation levels, and VAR compensators switching. The deviation from operation optimality will result in additional losses and additional operational cost of the power system. Reduction of the operational cost increases the power system efficiency and provides a significant reduction in total energy consumption. This paper proposes a mathematical model for minimizing the additional (add-on) costs based on Design of Experiments (DOE). The relation between add-on operational costs and OLTC settings is established by means of regression statistical analysis. The developed model is applied to a 20-bustest network. The regression curve fitting procedure requires simulation experiments which have been carried out by the DigSilent PowerFactory 13.2 Program for performing network power flow. The results show the effectiveness of the model. The research work raises the importance the power system operation management of the EPS where the Distribution System Operator can avoid the add-on operational costs by continuous correction to get an operation mode close to optimality

Characterizing and Diminishing Autofluorescence in Formalin-fixed Paraffin-embedded Human Respiratory Tissue

The article of record as published may be found at http://dx.doi.org/10.1369/0022155414531549Tissue autofluorescence frequently hampers visualization of immunofluorescent markers in formalin-fixed paraffin-embedded respiratory tissues. We assessed nine treatments reported to have efficacy in reducing autofluorescence in other tissue types. The three most efficacious were Eriochrome black T, Sudan black B and sodium borohydride, as measured using white light laser confocal Ʌ² (multi-lambda) analysis. We also assessed the impact of steam antigen retrieval and serum application on human tracheal tissue autofluorescence. Functionally fitting this Ʌ² data to 2-dimensional Gaussian surfaces revealed that steam antigen retrieval and serum application contribute minimally to autofluorescence and that the three treatments are disparately efficacious. Together, these studies provide a set of guidelines for diminishing autofluorescence in formalin-fixed paraffin-embedded human respiratory tissue. Additionally, these characterization techniques are transferable to similar questions in other tissue types, as demonstrated on frozen human liver tissue and paraffin-embedded mouse lung tissue fixed in different fixatives.NIHNIAI

IL-7 as a mucosal adjuvant in pulmonary immunization protocols

International audienceObjective: Mucosae are the gateway for many pathogens. However, few vaccines have been developed to specifically target mucosal immunity. Recent studies in the laboratory evidenced local expression of IL-7 in the acutely SIV-infected intestinal mucosa and IAV-infected lung in macaques or mice, respectively. This overexpression led to chemokine production and infiltration of immune cells into these mucosae. In addition, systemic injection of IL-7 to macaques rapidly stimulates both the production of chemokines and immune cells homing into the mucosa. These results prompted us to study if IL-7 could be used as a mucosal vaccine adjuvant.Methods: Mice were intratracheally treated with IL-7 or PBS, then immunized by the same route against diphtheria toxoid (DT) or inactivated influenza virus (IAVi) two days later. DT immunized-mice were sacrificed at day 14 while those immunized with IAVi were infected with virulent IAV at day 14 and sacrificed at day 29. We measured antigen-specific antibody responses (anti-DT & anti-IAV) in both bronchoalveolar lavages (BAL) and sera, as well as chemokine expressions in lung tissue, by ELISA. The immune cell infiltration into the pulmonary mucosa was evaluated by immunochemistry on lung sections. The effectiveness of IL-7-adjuvanted vaccine in providing protection against IAV pathology was assessed by daily monitoring of animal body weight.Results: Intratracheal administration of IL-7 stimulated the production of pro-inflammatory chemokines in the lung parenchyma, leading to massive infiltration of immune cells found to be mainly organized in lymphoid aggregates. Moreover, intratracheal administration of IL-7 before primo-immunization allowed antigens-specific IgAs and IgGs production in the pulmonary mucosa. These effects were not observed in control mice vaccinated without IL-7 administration. In addition, only IL-7-treated immunized mice were protected against influenza pathology. This protection seems to be related to a high level of IAV-specific antibodies in BAL and lymphoid aggregate appearance in the pulmonary mucosa.Conclusion: By attracting immune cells into mucosae, local IL-7 administration prepares the mucosal immune system, gathering conditions that result in enhanced antigen-specific pulmonary immune responses upon antigenic stimulation. Hence, IL-7 appears as a mucosal adjuvant able to increase mucosal antibody responses, an important immune arm implicated in the protection against most mucosal infections